<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CHLORAMPHENICOL</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CHLORAMPHENICOL</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#drugAction" data-toggle="tab">Drug action</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#lessSuitableForPrescribing" data-toggle="tab">Less suitable for prescribing</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Superficial eye infections</span>,
            </h4>
            <p class="specificity"><span class="route">To the eye using eye ointment</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 1 drop every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing, frequency dependent on the severity of the infection. For less severe infection 3&#8211;4 times daily is generally sufficient.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply daily, to be applied at night (if eye drops used during the day), alternatively apply 3&#8211;4 times a day, if ointment used alone.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply 1 drop every 2 hours then reduce frequency as infection is controlled and continue for 48 hours after healing, frequency dependent on the severity of the infection. For less severe infection 3&#8211;4 times daily is generally sufficient.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply daily, to be applied at night (if eye drops used during the day), alternatively apply 3&#8211;4 times a day, if ointment used alone.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Bacterial infection in otitis externa</span>,
            </h4>
            <p class="specificity"><span class="route">To the ear</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply 2&#8211;3 drops 2&#8211;3 times a day.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Apply 2&#8211;3 drops 2&#8211;3 times a day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Life threatening infections particularly those caused by <ph outputclass="organism"> <i>Haemophilus infuenzae</i> </ph></span>,
                <span class="indication">Typhoid fever</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth or by intravenous injection or by intravenous infusion</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                12.5 mg/kg every 6 hours, in exceptional cases dose can be doubled for severe infections such as septicaemia and meningitis, providing high doses reduced as soon as clinically indicated.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>


      <section class="tab-pane" id="drugAction">
        <h2>Drug action</h2>

            <section class="drugAction">
              <p>Chloramphenicol is a potent broad-spectrum antibiotic.</p>
            </section>
      </section>

      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Manufacturer advises avoid; neonatal &#8216;grey-baby syndrome&#8217; if used in third trimester.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Avoid unless essential&#8212;no information on <i>topical</i> use but risk of &#8216;neonatal grey-baby syndrome&#8217; with <i>oral</i> use in third trimester.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Reduce dose.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid if possible&#8212;increased risk of bone-marrow depression.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Avoid in severe renal impairment unless no alternative; dose-related depression of haematopoiesis.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> high incidence of sensitivity reactions to vehicle,
              </p>
              <p>
                <strong>notKnown:</strong> transient stinging, blood disorders, depression, diarrhoea, dry mouth, erythema multiforme, glossitis, grey syndrome in neonates, headache, nausea, nocturnal haemoglobinuria, optic neuritis, peripheral neuritis, reversible and irreversible aplastic anaemia (with reports of resulting leukaemia), stomatitis, urticaria, vomiting, blood disorders, depression, diarrhoea, dry mouth, erythema multiforme, glossitis, headache, nausea, nocturnal haemoglobinuria, optic neuritis, peripheral neuritis, reversible and irreversible aplastic anaemia (with reports of resulting leukaemia), stomatitis, urticaria, vomiting,
              </p>
        
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
                <p class="title">Grey syndrome</p>
              <p>Grey syndrome (abdominal distension, pallid cyanosis, circulatory collapse) may follow excessive doses in neonates with immature hepatic metabolism.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Associated with serious haematological side-effects when given systemically and should therefore be reserved for the treatment of life-threatening infections.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in children</h3>
              <p>Displacement value may be significant for injection, consult local guidelines. For intermittent intravenous infusion, dilute reconstituted solution further in glucose 5% or sodium chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in adults</h3>
              <p>For <i>intravenous infusion</i> (<i>Kemicetine</i>
            <tm tmtype="reg"/>), give intermittently or via drip tubing in Glucose 5% or Sodium chloride 0.9%.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Chloramphenicol ear drops for ear infections (otitis externa)</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/chloramphenicol-ear-drops-ear-infections-otitis-externa-0">www.medicinesforchildren.org.uk/chloramphenicol-ear-drops-ear-infections-otitis-externa-0</xref>
            </p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Chloramphenicol for eye infections</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/chloramphenicol-eye-infections-0">www.medicinesforchildren.org.uk/chloramphenicol-eye-infections-0</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>When used by ear:</strong>
            avoid prolonged use
          </li>
          <li>
              <strong>With intravenous use:</strong>
            avoid repeated courses and prolonged treatment
          </li>
          <li>
              <strong>With oral use:</strong>
            avoid repeated courses and prolonged treatment
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

          <h3>Therapeutic drug monitoring</h3>
        
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use in adults</h3>
              <p>Plasma concentration monitoring preferred in the elderly.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use in children</h3>
              <p>Plasma concentration monitoring preferred in those under 4&#8239;years of age.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use in neonates</h3>
              <p>Plasma concentration monitoring required in neonates. Grey baby syndrome may follow excessive doses in neonates with immature hepatic metabolism.</p>
            </section>
            <section class="therapeuticDrugMonitoring">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Recommended peak plasma concentration (approx. 2 hours after administration by mouth, intravenous injection or infusion) 10&#8211;25&#8239;mg/litre; pre-dose (&#8216;trough&#8217;) concentration should not exceed 15&#8239;mg/litre.</p>
            </section>
        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</h3>
              <p>Blood counts required before and periodically during treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">When used by <ph outputclass="route">ear</ph> in children</h3>
              <p>Licensed for use in children (age range not specified by manufacturers).</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Although multi-dose chloramphenicol eye drops commonly contain preservatives, preservative-free unit dose vials may be available.</p>
            </section>
      </section>



      <section class="tab-pane" id="lessSuitableForPrescribing">
        <h2>Conditions when less suitable for prescribing</h2>

            <section class="lessSuitableForPrescribing">
              <h3 class="specificity">When used by <ph outputclass="route">ear</ph></h3>
              <p>Chloramphenicol ear drops are less suitable for prescribing.</p>
            </section>
      </section>




      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">When used by <ph outputclass="route">eye</ph></h3>
              <p>Chloramphenicol 0.5% eye drops (in max. pack size 10&#8239;mL) and 1% eye ointment (in max. pack size 4&#8239;g) can be sold to the public for treatment of acute bacterial conjunctivitis in adults and children over 2 years; max. duration of treatment 5 days.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CHLORAMPHENICOL</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP75434"><a href="../medicinalForm/PHP75434.html" data-target="#PHP75434" data-action="load">Capsule</a></div>
            <div id="PHP75445"><a href="../medicinalForm/PHP75445.html" data-target="#PHP75445" data-action="load">Powder for solution for injection</a></div>
            <div id="PHP75440"><a href="../medicinalForm/PHP75440.html" data-target="#PHP75440" data-action="load">Ear drops</a></div>
            <div id="PHP75451"><a href="../medicinalForm/PHP75451.html" data-target="#PHP75451" data-action="load">Eye drops</a></div>
            <div id="PHP75428"><a href="../medicinalForm/PHP75428.html" data-target="#PHP75428" data-action="load">Eye ointment</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
